Meta AnalysisID 3884
疟疾对非洲地区多糖疫苗免疫应答的影响
CRD42019059464
Does Plasmodium falciparum malaria impair the immune response to heterologous polysaccharide vaccines in individuals with clinical or asymptomatic malaria in Africa?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 3884
- Evidence Id
- 12442
- Core Evidence Id
- 12442
- Source Meta Analysis Id
- 3841
- Herb2 Meta Analysis Id
- HBMA003841
- Crd Id
- CRD42019059464
- Title
- The effect of malaria on the immune response to polysaccharide vaccines in Africa
- Review Question
- Does Plasmodium falciparum malaria impair the immune response to heterologous polysaccharide vaccines in individuals with clinical or asymptomatic malaria in Africa?
- Study Type Included
- Observational or clinical trial studies of the vaccines defined under “Intervention(s), exposure(s) section”, including but not restricted to randomised clinical trials. We will only include studies in which the status of Plasmodium falciparum parasitemia has been documented at the moment of vaccination, and that have measured the antibody or cellular response in the individuals after vaccine administration.
- Condition Being Studied
- Vaccination is one of the most effective public health interventions. Access to vaccines is a universal right and international organizations as The Vaccine Alliance GAVI and the World Health Organization are leading a global effort to improve access to life-saving vaccines in poor countries. Of note, many of the countries that are the target of these initiatives are malaria-endemic countries. Malaria infection is a parasite vector-borne disease that impairs the normal function of the immune system. Importantly, there is evidence that malarial parasitemia impairs the immune response to polysaccharide vaccines in African children. Despite the great impact that this infection could have in malaria endemic countries on the protective effect of vaccinations and the incidence of vaccine preventable diseases, a study to assess this research question systematically has not been performed yet. We will conduct a systematic review of the immune response to polysaccharide vaccines in malaria-endemic countries in Africa. Vaccines to be studied will include polysaccharide vaccines that are part of the expanded program on immunization (EPI), as well as other polysaccharide vaccines in phase II-III-IV trials. The main aim of this review will be to compare the immune response to polysaccharide vaccines in individuals with and without malaria.
- Participant
- Inclusion criteria: Female and male individuals living in malaria endemic settings in Africa. Exclusion criteria: Individuals living outside Africa.
- Animal
- Human Disease Modelled
- Intervention
- Inclusion: Polysaccharide-based vaccines included in the EPI of African malaria endemic countries; as well as other polysaccharide vaccines in phase II-III-IV trials in African malaria endemic countries. Exclusion: Protein-based vaccines, except the ones listed under “Comparator(s)/control, Inclusion” section. Table 1. Polysaccharide-based vaccines: intervention vaccines EPI vaccines Haemophilus influenzae type b, Conjugated polysaccharide vaccine Streptococcus pneumoniae, bacterium Conjugated polysaccharide vaccine Neisseria meningitidis group A and C, Conjugated polysaccharide vaccine Non EPI vaccines Typhoid fever Salmonella enterica serovar typhi, Polysaccharide vaccine Group B Streptococcus (Streptococcus agalactiae), Polysaccharide vaccine/Conjugated polysaccharide vaccine.
- Comparator Control
- Inclusion: Protein antigen vaccines. Exclusion: BCG, Polio vaccines, Pertussis inactivated whole-cell vaccine, other vaccines except the ones specified under “Inclusion” criteria in this section. Table 2. Protein-based and live attenuated vaccines: control Corynebacterium diphtheria/Toxoid (inactivated toxin): DTP, DT, Td vaccines. Bordetella pertussis/Protein-based acellular: DTP. Clostridium tetani/Toxoid (inactivated toxin): TT, DTP, DT, Td. Plasmodium falciparum malaria 1. RTS, S vaccine; 2. Attenuated PfSPZ Vaccine 1. Recombinant protein-based malaria vaccine; 2. Irradiation attenuated whole sporozoite vaccine. Ebola: Recombinant vesicular stomatitis virus–Zaire Ebola virus vaccine (rVSV-ZEBOV; ChAd3-EBO-Z). Measles: Lived attenuated vaccine.
- Main Outcome
- 1) The immune response to vaccine administration: antibody or cellular response. 2) Malaria status at the moment of vaccine administration: measured in peripheral blood parasitemia by microscopic (thick blood smear) and/or molecular methods (quantitative polymerase chain reaction). 3) Time at which the immune response was measured, e.g. 1 month after third dose of the vaccine.
- Outcome Measure
- Additional Outcome
- 1) HIV status 2) Age 3) Nutritional status 4) Concomitant vaccines administrated 5) Haemoglobin status 6) Geohelminth co-infection status
- Study Method
- Systematic review
- Keyword
- Africa; Humans; Malaria; Malaria Vaccines; Polysaccharides
- Contact
- Gloria P. Gomez-Perez [email protected]
- Organisational Affiliation
- Amsterdam University Medical Centers, University of Amsterdam, The Netherlands www.amc.nl
- Funding Source
- Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 9, PO Box 22660, 1100 DD Amsterdam, The Netherlands.
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- Netherlands
- Review Stage
- Review Ongoing
- First Submission Date
- 2018-10-14
- Registration Date
- 2019-04-05
- Anticipated Start Date
- 2018-10-14
- Anticipated Completion Date
- 2019-06-30
- Title Cn
- 疟疾对非洲地区多糖疫苗免疫应答的影响
- Title En
- The effect of malaria on the immune response to polysaccharide vaccines in Africa
- Bilingual Status
- complete